Factor II

Balfaxar is used to reverse the effect of blood-thinning medicines like warfarin in adult patients who need urgent surgery or procedures to reduce the risk of bleeding. Balfaxar works to restore blood coagulation by increasing blood clotting factors that become low when taking warfarin tablets. Balfaxar is a non-activated four factor prothrombin complex concentrate (4F-PCC).  Balfaxar contains vitamin K-dependent factors Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S. The generic name for Balfaxar is prothrombin complex concentrate, human-lans. Warfarin and other vitamin K antagonists are prescribed to prevent blood clots in patients who have had a heart attack , heart valve surgery , stroke , deep vein thrombosis/pulmonary embolism, or for certain types of irregular heartbeat ( atrial fibrillation ). Patients on warfarin or vitamin K antagonists have an increased risk of bleeding if they need to have urgent surgery or invasive procedures. Balfaxar (prothrombin complex concentrate, human-lans) is able to quickly restore coagulation, to reduce the risk of bleeding.

Balfaxar is used to reverse the effect of blood-thinning medicines like warfarin in adult patients who need urgent surgery or procedures to reduce the risk of bleeding. Balfaxar works to restore blood coagulation by increasing blood clotting factors that become low when taking warfarin tablets. Balfaxar is a non-activated four factor prothrombin complex concentrate (4F-PCC).  Balfaxar contains vitamin K-dependent factors Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S. The generic name for Balfaxar is prothrombin complex concentrate, human-lans. Warfarin and other vitamin K antagonists are prescribed to prevent blood clots in patients who have had a heart attack , heart valve surgery , stroke , deep vein thrombosis/pulmonary embolism, or for certain types of irregular heartbeat ( atrial fibrillation ). Patients on warfarin or vitamin K antagonists have an increased risk of bleeding if they need to have urgent surgery or invasive procedures. Balfaxar (prothrombin complex concentrate, human-lans) is able to quickly restore coagulation, to reduce the risk of bleeding.

You should not take this medicine if you are allergic to prothrombin complex concentrate, human-lans, or any of the components of the product. have a known allergy to heparin or a history of heparin-induced thrombocytopenia (HIT). IgA deficient patients with known antibodies against IgA. Pregnancy It is not known whether this medicine can harm an unborn baby. Tell your doctor if you are pregnant or planning a pregnancy. Breastfeeding It is not known if this medicine passes into breast milk or what effect it may have on milk production or on the breastfeeding infant.

Get emergency medical help if you have signs of an allergic reaction to Balfaxar: hives , rash; nausea , vomiting , feeling light-headed; fast heartbeats; chest tightness, wheezing, difficulty breathing; swelling of your face, lips, tongue, or throat. Balfaxar side effects may include: low red blood cells (anemia) - pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; stomach pain weakness or lack of energy infusion site reaction complications of stitches and wound healing pain during the procedure vomiting during procedure painful urination

Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with this medicine in clinical trials and post-marketing surveillance. Patients receiving this medicine should be monitored for signs and symptoms of thromboembolic events. Restarting anticoagulation medicines should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding. This medicine may not be suitable for patients who have had thromboembolic events in the previous 3 months. This medicine is made from human plasma; therefore, may carry the risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Both fatal and non-fatal arterial and venous thromboembolic complications have been reported with this medicine in clinical trials and post-marketing surveillance. Patients receiving this medicine should be monitored for signs and symptoms of thromboembolic events. Restarting anticoagulation medicines should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding. This medicine may not be suitable for patients who have had thromboembolic events in the previous 3 months. This medicine is made from human plasma; therefore, may carry the risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

No adult dosage information is recorded for this medicine yet.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Other drugs may interact with the prothrombin complex, including prescription and over-the-counter medicines, vitamins , and herbal products . Tell your doctor about all your current medicines and any medicine you start or stop using.

Store at room temperature, or in refrigerator.